MedTrace Logo

GenoMed4ALL: Improving SCD Classification and Prognosis by AI

NCT06019208 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-04-12

No results posted yet for this study

Summary

GenoMed4All 'Genomics and Personalized Medicine for all though Artificial Intelligence in Haematological Diseases' aims to advance on individual SCD patients' disease characterisation and to improve the monitoring of patients' health status, optimise clinical therapy guidance and ultimately improved health outcomes by the identification of biomarkers and the development of individual (risk) models in SCD. Genomed4All supports the pooling of genomic, clinical data and other "-omics" health through a secure and privacy respectful data sharing platform based on the novel Federated Learning scheme, to advance research in personalised medicine in haematological diseases thanks to advanced Artificial Intelligence (AI) models and standardised interoperable sharing of cross-border data, without needing to directly share any sensitive clinical patients' data. The SCD Use case will gather multi-modal clinical and -OMICs data from 1,000 SCD patients in 4 EU-MS: France, Italy, Spain and The Netherlands.

In close collaboration with the European Reference Network on Rare Hematological Diseases (ERN-EuroBloodNet, GA101157011), GENOMED4ALL involves multiple clinical partners from the network, while leveraging on healthcare information and repositories that will be gathered incorporating interoperability standards as promoted by ERN-EuroBloodNet central registry, the European Rare Blood Disorders Platform.

Conditions

  • Sickle Cell Disorders

Sponsors & Collaborators

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Principal Investigators

  • Federico Alvarez · Universidad Politecnica de Madrid

  • Gastone Castellani · University of Bologna

  • Raffaella Colombatti · University of Padova

  • Eduard van Beers · UMC Utrecht

  • Marianne de Montalembert · APHP Necker

  • Pablo Bartolucci · APHP Henri Mondor

  • Tiziana Sanavia · University of Torino

  • Petros Kountouris · Cyprus Institute of Neurology and Genetics

  • Matteo Della Porta · Istituto Clinico Humanitas

  • Maria del Mar Mañú Pereira · Hospital Universitari Vall d'Hebron Research Institute

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-09-30
Completion
2024-12-31

Countries

  • France
  • Italy
  • Netherlands
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06019208 on ClinicalTrials.gov